ST. LOUIS, Dec. 27, 2010 /PRNewswire-FirstCall/ -- K-V Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing of its Form 10-K for its fiscal year ended March 31, 2010 with the Securities and Exchange Commission.  As a result, the Company has met the deadline for filing its delayed fiscal 2010 Form 10-K to enable its securities to continue trading on the New York Stock Exchange.

The Company is currently working on preparing and filing its quarterly reports on Form 10-Q for the quarters ended June 30, 2010 and September 30, 2010 and will file these reports as soon as they are completed.  The Company's Form 10-Q for the quarter ending December 31, 2010 will be due on February 9, 2011.  The Company currently expects that it will be unable to timely file this report.

Greg Divis, KV's Chief Executive Officer stated, "We are pleased to have filed our Form 10-K for fiscal 2010 and continue to work diligently and as quickly as possible to file the remaining outstanding quarterly reports to enable us to return to a current and timely filer with the Securities and Exchange Commission.  The Company continues to move forward as we focus on returning additional products to the market prior to our 2011 fiscal year-end and to the approval and launch of Gestiva™."

About K-V Pharmaceutical Company

K-V Pharmaceutical Company is a fully-integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded prescription pharmaceutical products.  The company markets its technology-distinguished products through Ther-Rx Corporation, its branded drug subsidiary.  For further information about K-V Pharmaceutical Company, please visit the company's corporate Web site at

Cautionary Note Regarding Forward-looking Statements

This press releases contains various